Spero Therapeutics (SPRO) Profit After Tax Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 65.80% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 17.05% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 48.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.05% |
| Dec 31, 2025 | 250.58% |
| Sep 30, 2025 | 56.83% |
| Jun 30, 2025 | 90.48% |
| Mar 31, 2025 | -9.45% |
| Dec 31, 2024 | -140.82% |
| Sep 30, 2024 | -434.38% |
| Jun 30, 2024 | -49.92% |
| Mar 31, 2024 | 4.50% |
| Dec 31, 2023 | 91.27% |
| Sep 30, 2023 | 72.59% |
| Jun 30, 2023 | 58.46% |
| Mar 31, 2023 | 59.59% |
| Dec 31, 2022 | 191.42% |
| Sep 30, 2022 | 48.16% |
| Jun 30, 2022 | -54.44% |
| Mar 31, 2022 | -69.02% |
| Dec 31, 2021 | -57.57% |
| Sep 30, 2021 | -18.93% |
| Jun 30, 2021 | -6.12% |
| Mar 31, 2021 | 16.49% |
| Dec 31, 2020 | 25.62% |
| Sep 30, 2020 | -6.88% |
| Jun 30, 2020 | -33.09% |
| Mar 31, 2020 | -358.56% |
| Dec 31, 2019 | -135.74% |
| Sep 30, 2019 | -69.33% |
| Jun 30, 2019 | -32.08% |
| Mar 31, 2019 | 52.35% |
| Dec 31, 2018 | 23.57% |
| Sep 30, 2018 | -6.29% |
| Jun 30, 2018 | -1.98% |
| Mar 31, 2018 | -81.14% |
| Dec 31, 2017 | -69.18% |
| Sep 30, 2017 | -55.86% |